Study rates safety of different testosterone preparations
Short-acting testosterone injections are associated with greater risk of cardiovascular events, hospitalizations, and death compared with gels or patches, according to a large retrospective cohort study published online in JAMA Internal Medicine. MedPage Today (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 14, 2015 Category: Endocrinology Source Type: news
Testosterone Drugs May Be Overused, FDA Warns
WASHINGTON (AP) — The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related issues like low libido and fatigue.
The agency says drugmakers must clearly state in their labeling and promotions that the drugs, currently taken by millions of U.S. men, are only approved to treat low testosterone levels caused by disease or injury, not normal aging. Additionally, the FDA cautioned that the drugs may increase the risk of heart attack, stroke and other cardiovascular problem...
Source: Science - The Huffington Post - March 3, 2015 Category: Science Source Type: news
Testosterone Treatment Lawsuit News: New Filing Alleges...
The Firm is evaluating testosterone lawsuits on behalf of men who suffered serious cardiovascular events, allegedly due to their use of Depo-Testosterone and other prescription low testosterone...(PRWeb August 22, 2014)Read the full story at http://www.prweb.com/releases/testosterone-lawsuit/depo-testosterone-lawsuit/prweb12115284.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 23, 2014 Category: Pharmaceuticals Source Type: news
Delatestryl (Testosterone Enanthate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 7, 2014 Category: Drugs & Pharmacology Source Type: news
Low Testosterone Lawsuits Transferred to Federal Multidistrict...
All Pending and Future Testosterone Lawsuits Filed in Federal Courts Involving AndroGel, Axiron, Testim, Foresta, AndroDerm and Depo-Testosterone Will be Transferred to the U.S. District Court,...(PRWeb June 18, 2014)Read the full story at http://www.prweb.com/releases/2014/06/prweb11949048.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 19, 2014 Category: Pharmaceuticals Source Type: news
Low Testosterone Lawsuits Transferred to Federal Multidistrict...
All Pending and Future Testosterone Lawsuits Filed in Federal Courts Involving AndroGel, Axiron, Testim, Foresta, AndroDerm and Depo-Testosterone Will be Transferred to the U.S. District Court,...(PRWeb June 10, 2014)Read the full story at http://www.prweb.com/releases/2014/06/prweb11930045.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 10, 2014 Category: Pharmaceuticals Source Type: news
Endo's Testosterone Injection Finally Wins FDA Nod
(MedPage Today) -- Testosterone undecanoate for injection (Aveed) has received the FDA's approval for treating male hypogonadism on its third try, its manufacturer announced. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 6, 2014 Category: Geriatrics Source Type: news
Mother is diagnosed with cancer on her NECK after taking her son to the doctors over worrying spot on his head
Marie Testro, 43, from Derby, took her son Billy to their family GP after she became worried about a spot on his hairline. (Source: the Mail online | Health)
Source: the Mail online | Health - January 23, 2014 Category: Consumer Health News Source Type: news
FDA Rejects Long-Acting Testosterone Injection for Third TimeFDA Rejects Long-Acting Testosterone Injection for Third Time
In a decision that will surprise few people, the FDA has once again refused approval for long-acting testosterone undecanoate injection for male hypogonadism. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 31, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
FDA staff concerned about safety of Endo's testosterone injection
(Reuters) - Reviewers for the U.S. Food and Drug Administration said safety data on Endo Health Solutions Inc's twice-rejected testosterone injection Aveed was "concerning" and showed that the therapy was associated with severe and immediate post-injection adverse events. (Source: Reuters: Health)
Source: Reuters: Health - April 16, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
